|
|
|
|
G Medical Innovations Holdings Ltd (GMVD) |
|
Price: $0.1810
$0.00 
0.000%
|
| Day's High:
| $0.2038
| Week Perf:
| 2.84 %
|
| Day's Low: |
$ 0.16 |
30 Day Perf: |
-46.05 % |
| Volume (M): |
2,862 |
52 Wk High: |
$ 8.49 |
| Volume (M$): |
$ 518 |
52 Wk Avg: |
$1.44 |
| Open: |
$0.16 |
52 Wk Low: |
$0.14 |
|
|
| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
0 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
25 |
| Cash Flow (TTM) (Millions $) |
6 |
| Capital Exp. (TTM) (Millions $) |
0 |
G Medical Innovations Holdings Ltd
Company Address: 5 Oppenheimer, Rehovot 7670105
Company Phone Number: 8 958 4777 Stock Exchange / Ticker: NASDAQ GMVD
| GMVD is expected to report next financial results on May 15, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Aurora Technology Acquisition Corp
An Overview of Aurora Technology Acquisition Corp's Third Quarter Earnings
As the July to September 30, 2023 earnings season progresses, various companies across different industries are reporting their financial results. One such industry is the Medical Equipment and Supplies sector, which has seen many corporations release their earnings reports. Among them is Aurora Technology Acquisition Corp (ATAK), which recently announced an operating deficit of -$0.4793 million for the third quarter of 2023.
Comparing this figure to the same period in 2022, we can observe a deteriorating operating deficit. In the third quarter of 2022, ATAK reported an operating deficit of -$0.21933 million. This decline raises questions among market participants about the company's ability to generate revenue.
|
|
Vivos Therapeutics Inc
For the fiscal time-frame closing September 30 2023 Vivos Therapeutics Inc decreased a loss per share of $-1.75 per share compare to $-6.50 a year before and Income per Share improved from $-4.50 per share from the preceding reporting season. The revenue crumbled by -31.748 % to $2.90 million from $4.25 million in the corresponding reporting season a year before and sequentially Revenue decreased by -6.456 % from $3.10 million.
|
|
Vystar Corporation
Over the past five days, Vystar Corporation has experienced a significant drop in its stock price, declining by -37.78%. Furthermore, the stock is currently trading -20.9% below its 52-week average. In order to better understand the reasons behind this decline, it is essential to examine Vystar Corporation's financial performance for the recent reporting season, which ended on September 30, 2023.
Earnings Per Share and Revenue:
Vystar Corporation reported a considerable improvement in its financial health compared to the previous year. The loss per share decreased from $-0.23 to $-0.03, while the income per share improved from $-0.04. In terms of revenue, there was a significant decline of -98.311% from $3.57 million to $0.06 million compared to the same reporting season a year prior. However, sequentially, the revenue saw an increase of 67.054% from $0.04 million.
|
|
Petvivo Holdings Inc
As an investor closely following Petvivo Holdings Inc, the recent financial results have presented a mixed bag of challenges and opportunities. In the second quarter of 2024, the company experienced lower turnover, resulting in a significant revenue decrease and a larger shortfall per share compared to the previous year. However, there were notable signs of potential growth and increasing demand within the Medical Equipment and Supplies industry.
One of the key financial indicators is the revenue, which decreased by -7.127% to $0.21 million year on year. This decline is concerning for Petvivo Holdings Inc, as it points to potential shortcomings in the company's ability to generate sales. Comparatively, the Medical Equipment and Supplies industry as a whole recorded a top-line rise in the same period, suggesting that Petvivo may be facing certain internal challenges.
|
|
Ir Med Inc
As an observer of the Medical Equipment and Supplies sector, I have thoroughly analyzed the third quarter financial results of Ir Med Inc. The company's performance took center stage in this report, overshadowing the same period in the previous year. Despite operating predominantly in the development phase, Ir Med Inc showcased a bullish quarter, signaling potential growth prospects.
Notably, Ir Med Inc reported an operating profit of $1.197 million for the July to September 30, 2023 quarter, without any reported revenue. This indicates that the company is focusing on developing its services rather than generating immediate revenue. Such a strategic course of action is crucial for a business aiming to establish a strong foundation before entering the market.
|
| Per Share |
Current |
| Earnings (TTM) |
-34.17 $ |
| Revenues (TTM) |
6131.62 $
|
| Cash Flow (TTM) |
8370.63 $ |
| Cash |
409.24 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-34.17 $
|
| Revenues (TTM) |
6131.62 $ |
| Cash Flow (TTM) |
8370.63 $ |
| Cash |
409.24 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
